CARPETS: A Phase I Open Label Study of the Safety and Immune effects of an Escalating Dose of Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T Cells in Patients with Metastatic BRAF-Mutant and GD2-Positive Melanoma

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1010386

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Malignant melanoma is increasing in incidence in Australia. Current drugs for advanced melanoma are only sometimes effective. BRAF blocking drugs with promising anti-melanoma activity are being tested in Australia but drug resistance is developing. We will genetically engineer the patient’s own T cells to redirect them against the melanoma. The feasibility, safety, and immune effects of this approach will be tested in patients whose advanced melanoma is no longer responding to BRAF blockers.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $351,583.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cell immunotherapy | clinical trial | gene therapy | immune response | melanoma | melanoma antigens

Related Links